ARS Pharmaceuticals Net Tangible Assets

ARS Pharmaceuticals (SPRY) currently reports a net tangible assets of $13M as of June 2026. That compares with $190M in the prior-year period — down 93.5% year over year. Use the charts on this page to explore ARS Pharmaceuticals's net tangible assets history and peer comparisons.

ARS Pharmaceuticals's net tangible assets decreased from $190M to $13M — a 93.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARS Pharmaceuticals reported $13M in net tangible assets as of June 2026. That compares with $190M in the prior-year period — down 93.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARS Pharmaceuticals, and consider following SPRY for alerts when major investors trade the stock.

ARS Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRY with unrelated industries.